Study #2024-0033
A platform study of RAS(ON) inhibitor combinations in patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
MD Anderson Study Status
Not Accepting
Treatment Agent
RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, RMC-9805
Description
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with each other. The first three subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
Study phase:
Physician name:
Ferdinandos Skoulidis
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-943-5165
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.